-
Your selected country is
New Zealand
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Western blot analysis of Mitosin on a Jurkat cell lysate (Human T-cell leukemia; ATCC TIB-152). Lane 1: 1:1000, lane 2: 1:2000, lane 3: 1:4000 dilution of the mouse anti-human Mitosin antibody.
Immunofluorescence staining of human endothelial cells.
BD Transduction Laboratories™ Purified Mouse Anti-Human Mitosin
BD Transduction Laboratories™ Purified Mouse Anti-Human Mitosin
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
Western blot: Please refer to http://www.bdbiosciences.com/pharmingen/protocols/Western_Blotting.shtml
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
Companion Products
Mitosin, a nuclear proetin of 3113 amino acids, contains a pair of tandem repeats and seven leucine repeats. In vitro, Mitosin directly interacts with the retinoblastoma protein, Rb. Mitosin is expressed throughout the cell cycle, with levels being lowest during G1, and it localizes at the kinetochore during the mitotic phase. The subcellular redistribution of Mitosin to the kinetochore is linked to its phosphorylation. Its expression is linked to patients with autoimmune diseases characterized by abnormal cell proliferation. Ectopic expression of a truncated version of Mitosin blocks the progression of the cell cycle. This suggests that the protein has an important role during cell proliferation. Because of similarities in subcellular localization and expression, Mitosin and the autoantigen p300/CENP-F, which is also linked to a multitude of autoimmune disorders, are probably the same protein.
Development References (5)
-
Casiano CA, Humbel RL, Peebles C, Covini G, Tan EM. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Immunol. 1995; 8(4):575-586. (Biology). View Reference
-
Landberg G, Erlanson M, Roos G, Tan EM, Casiano CA. Nuclear autoantigen p330d/CENP-F: a marker for cell proliferation in human malignancies. Cytometry. 1996; 25(1):90-98. (Biology). View Reference
-
Rattner JB, Rao A, Fritzler MJ, Valencia DW, Yen TJ. CENP-F is a .ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Motil Cytoskeleton. 1993; 26(3):214-226. (Biology). View Reference
-
Trinkle-Mulcahy L, Andrews PD, Wickramasinghe S, et al. Time-lapse imaging reveals dynamic relocalization of PP1gamma throughout the mammalian cell cycle. Mol Biol Cell. 2003; 14(1):107-117. (Biology: Immunofluorescence). View Reference
-
Zhu X, Mancini MA, Chang KH, et al. Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression. Mol Cell Biol. 1995; 15(9):5017-5029. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.
Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.